Congenital cytomegalovirus infection: Molecular mechanisms mediating viral pathogenesis

Infectious Disorders - Drug Targets

Volumn 11, Issue 5, 2011, Pages 449-465

  Schleiss, Mark R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Congenital CMV infection; Cytomegalovirus; Immune evasion; Pathogenesis; Vaccine

Indexed keywords

CYTOMEGALOVIRUS VACCINE; GENE PRODUCT; MICRORNA; RNA;

APOPTOSIS; ARTICLE; BLOOD VESSEL INJURY; CARCINOGENESIS; CELL CYCLE; CELL PROLIFERATION; CHROMOSOME BREAKAGE; CONGENITAL CYTOMEGALOVIRUS INFECTION; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; DISABILITY; FETUS DEVELOPMENT; GENE EXPRESSION; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNE RESPONSE; IMMUNOMODULATION; INFECTION CONTROL; INFLAMMATION; INNATE IMMUNITY; NONHUMAN; PERCEPTION DEAFNESS; PLACENTA; UNITED STATES; VIRUS GENE; VIRUS PATHOGENESIS; VISUAL IMPAIRMENT;

EID: 80054100952     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152611797636721     Document Type: Article

References (190)

1. Weller, T.H. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. I. N. Engl. J. Med., 1971, 285 (4), 203-214.
2. Weller, T.H. The cytomegaloviruses: ubiquitous agents with protean clinical manifestations. II. N. Engl. J. Med., 1971, 285 (5), 267-274.
3. Boeckh, M.; Nichols, W.G.; Papanicolaou, G.; Rubin, R.; Wingard, J.R.; Zaia, J. Cytomegalovirus in hematopoietic stem cell transplant recipients: current status, known challenges, and future strategies. Biol. Blood Marrow Transplant., 2003, 9 (9), 543-558.
4. Jacobsen, M.A.; Mills, J. Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS): clinical findings, diagnosis, and treatment. Ann. Intern. Med., 1988, 108 (4), 585-594.
5. Nigro, G. Maternal-fetal cytomegalovirus infection: from diagnosis to therapy. J. Matern. Fetal Neonatal. Med., 2009, 22 (2), 169-174.
6. Nyholm, J; Schleiss, M.R. Prevention of maternal cytomegalovirus infection: current status and future prospects. Int. J. Wom. Health, 2010, 2, 23-35.
7. Kenneson, A.; Cannon, M.J. Review and meta-analysis of the epidemiology of congenital cytomegalovirus (CMV) infection. Rev. Med. Virol., 2007, 17 (4), 253-276.
8. Cannon, M.J.; Finn Davis, K. Washing our hands of the congenital cytomegalovirus disease epidemic. BMC Public Health, 2005, 5, 70-77.
9. Cheeran, M.C.; Lokensgard, J.R.; Schleiss, M.R. Neuropathogenesis of congenital cytomegalovirus infection: disease mechanisms and prospects for intervention. Clin. Microbiol. Rev., 2009, 22 (1), 99-126.
10. Boppana, S.B.; Rivera, L.B.; Fowler, K.B.; Mach, M.; Britt, W.J. Intrauterine transmission of cytomegalovirus to infants of women with preconceptional immunity. N. Engl. J. Med., 2001, 344 (18), 1366-1371.
11. Yamamoto, A.Y.; Mussi-Pinhata, M.M.; Boppana, S.B.; Novak, Z.; Wagatsuma, V.M.; Oliveira, P.D.; Duarte, G.; Britt, W.J. Human cytomegalovirus reinfection is associated with intrauterine transmission in a highly cytomegalovirus-immune maternal population. Am. J. Obstet. Gynecol., 2010, 202 (3), 297, e1-e8.
12. Ross, S.A.; Arora, N.; Novak, Z.; Fowler, K.B.; Britt, W.J.; Boppana, S.B. Cytomegalovirus reinfections in healthy seroimmune women. J. Infect. Dis., 2010, 201 (3), 386-389.
13. Fowler, K.B.; Stagno, S.; Pass, R.F.; Britt, W.J.; Boll, T.J.; Alford, C.A. The outcome of congenital cytomegalovirus infection in relation to maternal antibody status. N. Engl. J. Med., 1992, 326 (10), 663-667.
14. Revello, M.G.; Gerna, G. Diagnosis and management of human cytomegalovirus infection in the mother, fetus, and newborn infant. Clin. Microbiol. Rev., 2002, 15 (4), 680-715.
15. Bernstein, D.I. Vaccines for cytomegalovirus vaccines. Infect. Disord. Drug Targets., 2011, 11, 514-525.
16. Britt, W. Manifestations of human cytomegalovirus infection: proposed mechanisms of acute and chronic disease. Curr. Top. Microbiol. Immunol., 2008, 325, 417-470.
17. Pass, R.F., Fowler, K.B., Boppana, S.B., Britt, W.J.; Stagno, S. Congenital cytomegalovirus infection following first trimester maternal infection: symptoms at birth and outcome. J. Clin. Virol., 2006, 35 (2), 216-220.
18. Fisher, S.; Genbacev, O.; Maidji, E.; Pereira, L. Human cytomegalovirus infection of placental cytotrophoblasts in vitro and in utero: implications for transmission and pathogenesis. J. Virol., 2000, 74 (15), 6808-6820.
19. Lazzarotto, T.; Varani, S.; Guerra, B.; Nicolosi, A.; Lanari, M.; Landini, M.P. Prenatal indicators of congenital cytomegalovirus infection. J. Pediatr., 2000, 137 (1), 90-95.
20. Challacombe, J.F.; Rechtsteiner, A.; Gottardo, R.; Rocha, L.M.; Browne, E.P.; Shenk, T.; Altherr, M.R.; Brettin, T.S. Evaluation of the host transcriptional response to human cytomegalovirus infection. Physiol. Genomics, 2004, 18 (1), 51-62.
21. Arav-Boger, R., Battaglia, C.A.; Lazzarotto, T.; Gabrielli, L.; Zong, J.C.; Hayward, G.S.; Diener-West, M.; Landini, M.P. Cytomegalovirus (CMV)-encoded UL144 (truncated tumor necro sis factor receptor) and outcome of congenital CMV infection. J. Infect. Dis., 2006, 194 (4), 464-473.
22. Schleiss, M.R. Persistent and recurring viral infections: the human herpesviruses. Curr. Probl. Pediatr. Adolesc. Health Care, 2009, 39 (1), 7-23.
23. Chen, D.H.; Jiang, H.; Lee, M.; Liu, F.; Zhou, Z.H. Threedimensional visualization of tegument/capsid interactions in the intact human cytomegalovirus. Virology, 1999, 260 (1), 10-16.
24. Landini, M.P.; La Placa, M. Humoral immune response to human cytomegalovirus proteins: a brief review. Comp. Immun. Microbiol. Infect. Dis., 1991, 14 (2), 97-105.
25. Kern, F.; Bunde, T.; Faulhaber, N.; Kiecker, F.; Khatamzas, E.; Rudawski, I.M.; Pruss, A.; Gratama, J.W.; Volkmer-Engert, R.; Ewert, R.; Reinke, P.; Volk, H.D.; Picker, L.J. Cytomegalovirus (CMV) phosphoprotein 65 makes a large contribution to shaping the T cell repertoire in CMV-exposed individuals. J. Infect. Dis., 2002, 185 (12), 1709-1716.
26. Navarro, D.; Lennette, E.; Tugizov, S.; Pereira, L. Humoral immune response to functional regions of human cytomegalovirus glycoprotein B. J. Med. Virol., 1997, 52 (4), 451-459.
27. Rasmussen, L.; Matkin, C.; Spaete, R.; Pachl, C.; Merigan, T.C. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans. J. Infect. Dis., 1991, 164 (5), 835-842.
28. Mach, M.; Kropff, B.; Dal Monte, P.; Britt, W. Complex formation by human cytomegalovirus glycoproteins M (gpUL100) and N (gpUL73). J. Virol., 2000, 74 (24), 11881-11892.
29. Ryckman, B.J.; Jarvis, M.A.; Drummond, D.D.; Nelson, J.A.; Johnson, D.C. Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion. J. Virol., 2006, 80 (2), 710-722.
30. Wang, D.; Shenk, T. Human cytomegalovirus virion protein complex required for epithelial and endothelial cell tropism. Proc. Natl. Acad. Sci. USA, 2005, 102 (50), 18153-18158.
31. Irmiere, A., Gibson, W. Isolation and characterization of a noninfectious virion-like particle released from cells infected with human strains of cytomegalovirus. Virology, 1983, 130 (1), 118-133.
32. Pepperl, S.; Munster, J.; Mach, M.; Harris, J.R.; Plachter, B. Dense bodies of human cytomegalovirus induce both humoral and cellular immune responses in the absence of viral gene expression. J. Virol., 2000, 74 (13), 6132-6146.
33. Mersseman, V.; Böhm, V.; Holtappels, R.; Deegen, P.; Wolfrum, U.; Plachter, B.; Reyda, S. Refinement of strategies for the development of a human cytomegalovirus dense body vaccine. Med. Microbiol. Immunol., 2008, 197 (2), 97-107.
34. Bresnahan, W.A.; Shenk, T. A subset of viral transcripts packaged within human cytomegalovirus particles. Science, 2000, 288 (5475), 2373-2376.
35. Sarcinella, E.; Brown, M.; Tellier, R.; Petric, M.; Mazzulli, T. Detection of RNA in purified cytomegalovirus virions. Virus Res., 2004, 104 (2), 129-137.
36. Varnum, S.M.; Streblow, D.N.; Monroe, M.E.; Smith, P.; Auberry, K.J.; Pasa-Tolic, L; Wang, D.; Camp, D.G. 2nd; Rodland, K.; Wiley, S.; Britt, W.; Shenk, T.; Smith, R.D.; Nelson, J.A. Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J. Virol., 2004, 78 (20), 10960-10966.
37. Tandon, R.; AuCoin, D.P.; Mocarski, E.S. Human cytomegalovirus exploits ESCRT machinery in the process of virion maturation. J. Virol., 2009, 83 (20), 10797-10807.
38. Moorman, N.J.; Sharon-Friling, R.; Shenk, T.; Cristea, I.M. A targeted spatial-temporal proteomic approach implicates multiple cellular trafficking pathways in human cytomegalovirus virion maturation. Mol. Cell Proteomics, 2010, 9 (5), 851-860.
39. Phillips, S.L.; Bresnahan, W.A. Identification of binary interactions between human cytomegalovirus virion proteins. J. Virol., 2011, 85 (1), 440-447.
40. Mocarski, E.S.; Shenk, T.; Pass, R.F; Cytomegaloviruses. In Fields' Virology, Volume 1, Ed. 5. Bernard N. Fields, David Mahan Knipe, Peter M. Howley. Lippincott Williams & Wilkins, 2007, Chapter 69, pp. 2701-2772.
41. Chee, M.S.; Bankier, A.T.; Beck, S.; Bohni, R.; Brown, C.M.; Cerny, R.; Horsnell, T.; Hutchison, C.A. 3rd; Kouzarides, T.; Martignetti J.A.; Preddie, E.; Satchwell, S.C.; Tomlinson, P.; Weston, K.M.; Barrell, B.G. Analysis of the protein-coding content of the sequence of human cytomegalovirus strain AD169. Curr. Top. Microbiol. Immunol., 1990, 154, 125-169.
42. Cha, T.A.; Tom, E.; Kemble, G.W.; Duke, G.M.; Mocarski, E.S.; Spaete, R.R. Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J. Virol., 1996, 70, 78-83.
43. Bradley, A.J.; Lurain, N.S.; Ghazal, P.; Trivedi, U.; Cunningham, C.; Baluchova, K.; Gatherer, D.; Wilkinson, G.W.; Dargan, D.J.; Davison, A.J. High-throughput sequence analysis of variants of human cytomegalovirus strains Towne and AD169. J. Gen. Virol., 2009, 90, 2375-2380.
44. Davison, A.J.; Dolan, A.; Akter, P.; Addison, C.; Dargan, D.J.; Alcendor, D.J.; McGeoch, D.J.; Hayward, G.S. The human cytomegalovirus genome revisited: comparison with the chimpanzee cytomegalovirus genome. J. Gen. Virol., 2003, 84, 17-28.
45. Dolan, A.; Cunningham, C; Hector, R.D.; Hassan-Walker, A.F.; Lee, L.; Addison, C.; Dargan, D.J.; McGeoch, D.J.; Gatherer, D.; Emery, V.C.; Griffiths, P.D.; Sinzger, C.; McSharry, B.P.; Wilkinson, G.W.; Davison, A.J. Genetic content of wild-type human cytomegalovirus. J. Gen. Virol., 2004, 85, 1301-1312.
46. Murphy, E.; Shenk, T. Human cytomegalovirus genome. Curr. Top. Microbiol. Immunol., 2008, 325, 1-19.
47. Jung, G.S.; Kim, Y.Y.; Kim, J.I.; Ji, G.Y.; Jeon, J.S.; Yoon, H.W.; Lee, G.C.; Ahn, J.H.; Lee, K.M.; Lee, C.H. Full genome sequencing and analysis of human cytomegalovirus strain JHC isolated from a Korean patient. Virus Res., 2011, 156(1-2), 113-120.
48. Brondke, H.; Schmitz, B.; Doerfler W. Nucleotide sequence comparisons between several strains and isolates of human cytomegalovirus reveal alternate start codon usage. Arch. Virol., 2007, 152(11), 2035-2046.
49. Wang, A.; Ren, L.; Abenes, G.; Hai, R. Genome sequence divergences and functional variations in human cytomegalovirus strains. FEMS Immunol. Med. Microbiol. 2009, 55(1), 23-33.
50. Dargan, D.J.; Douglas, E.; Cunningham, C.; Jamieson, F.; Stanton, R.J.; Baluchova, K.; McSharry, B.P.; Tomasec, P.; Emery, V.C.; Percivalle, E.; Sarasini, A.; Gerna, G.; Wilkinson, G.W.; Davison, A.J. Sequential mutations associated with adaptation of human cytomegalovirus to growth in cell culture. J. Gen. Virol. 2010, 91, 1535-1546.
51. Cunningham, C.; Gatherer, D.; Hilfrich, B.; Baluchova, K.; Dargan, D.J.; Thomson, M.; Griffiths, P.D.; Wilkinson, G.W.; Schulz, T.F.; Davison, A.J. Sequences of complete human cytomegalovirus genomes from infected cell cultures and clinical specimens. J. Gen. Virol., 2009, 91, 605-615.
52. Adachi-Yamada, T.; O'Connor, M.B. Mechanisms for removal of developmentally abnormal cells: cell competition and morphogenetic apoptosis. J. Biochem., 2004, 136 (1), 13-17.
53. Benedict, C.A. Viruses and the TNF-related cytokines, an evolving battle. Cytokine Growth Factor Rev., 2003, 14 (3-4), 349-357.
54. Benedict, C.A.; Norris, P.S.; Ware, C.F. To kill or be killed: viral evasion of apoptosis. Nat. Immunol., 2002, 3 (11), 1013-1018.
55. Zhu, H.; Shen, Y.; Shenk, T. Human cytomegalovirus IE1 and IE2 proteins block apoptosis. J. Virol., 1995, 69 (12), 7960-7970.
56. Tsai, H.L.; Kou, G.H.; Chen, S.C.; Wu, C.W.; Lin, Y.S. Human cytomegalovirus immediate-early protein IE2 tethers a transcriptional repression domain to p53. J. Biol. Chem., 1996, 271 (7), 3534-3540.
57. Goldmacher, V. S.; Bartle, L.M.; Skaletskaya, A.; Dionne, C.A.; Kedersha, N.L.; Vater, C.A.; Han, J.W.; Lutz, R.J.; Watanabe, S.; Cahir McFarland, E.D.; Kieff, E.D.; Mocarski, E.S.; Chittenden, T. A cytomegalovirus-encoded mitochondria-localized inhibitor of apoptosis structurally unrelated to Bcl-2. Proc. Natl. Acad. Sci. USA, 1999, 96 (22), 12536-12541.
58. Reboredo, M.; Greaves, R.F.; Hahn, G. Human cytomegalovirus proteins encoded by UL37 exon 1 protect infected fibroblasts against virus-induced apoptosis and are required for efficient virus replication. J. Gen. Virol., 2004, 85 (pt. 12), 3555-3567.
59. Skaletskaya, A.; Bartle, L.M.; Chittenden, T.; McCormick, A.L.; Mocarski, E.S.; Goldmacher, V.S. A cytomegalovirus-encoded inhibitor of apoptosis that suppresses caspase-8 activation. Proc. Natl. Acad. Sci. USA, 2001, 98 (14), 7829-7834.
60. Williamson, C.D.; Zhang, A.; Colberg-Poley, A.M. The human cytomegalovirus protein UL37 exon 1 associates with internal lipid rafts. J. Virol., 2011, 85 (5), 2100-2111.
61. McCormick, A.L. Control of apoptosis by human cytomegalovirus. Curr. Top. Microbiol. Immunol., 2008, 325, 281-295.
62. Zhao, J.; Sinclair, J.; Houghton, J.; Bolton, E.; Bradley, A.; Lever, A. Cytomegalovirus beta 2.7 RNA transcript protects endothelial cells against apoptosis during ischemia/reperfusion injury. J. Heart Lung Transplant., 2010, 29 (3), 342-345.
63. Kern, E.R. Pivotal role of animal models in the development of new therapies for cytomegalovirus infections. Antiviral Res., 2006, 71 (2-3), 164-171.
64. Jurak, I.; Brune, W. Induction of apoptosis limits cytomegalovirus cross-species infection. EMBO J., 2006, 25 (11), 2634-2642.
65. Schumacher, U.; Handke, W.; Jurak, I.; Brune, W. Mutations in the M112/M113-coding region facilitate murine cytomegalovirus replication in human cells. J. Virol., 2010, 84 (16), 7994-8006.
66. Dehay, C.; Kennedy, H. Cell-cycle control and cortical development. Nat. Rev. Neurosci., 2007, 8 (6), 438-450.
67. Bresnahan, W.A.; Boldogh, I.; Thompson, E.A.; Albrecht, T. Human cytomegalovirus inhibits cellular DNA synthesis and arrests productively infected cells in late G1. Virology, 1996, 224 (1), 150-160.
68. Jault, F.M.; Jault, J.M.; Ruchti, F.; Fortunato, E.A.; Clark, C.; Corbeil, J.; Richman, D.D.; Spector, D.H. Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. J. Virol., 1995, 69 (11), 6697-6704.
69. Lu, M.; Shenk, T. Human cytomegalovirus infection inhibits cell cycle progression at multiple points, including the transition from G1 to S. J. Virol., 1996, 70 (12), 8850-8857.
70. Song, Y.J.; Stinski, M.F. Effect of the human cytomegalovirus IE86 protein on expression of E2F-responsive genes: a DNA microarray analysis. Proc. Natl. Acad. Sci. USA, 2002, 99 (5), 2836-2841.
71. Du, G.; Dutta, N.; Lashmit, P.; Stinski, M.F. Alternative splicing of the human cytomegalovirus major immediate-early genes affects infectious-virus replication and control of cellular cyclin-dependent kinase. J. Virol., 2011, 85 (2), 804-817.
72. Arcangeletti, M.C.; Rodighiero, I.; Mirandola, P.; De Conto, F.; Covan, S.; Germini, D.; Razin, S.; Dettori, G.; Chezzi, C. Cellcycle- dependent localization of human cytomegalovirus UL83 phosphoprotein in the nucleolus and modulation of viral gene expression in human embryo fibroblasts in vitro. J. Cell. Biochem., 2011, 112 (1), 307-317.
73. Petrik, D.T.; Schmitt, K.P.; Stinski, M.F. Inhibition of cellular DNA synthesis by the human cytomegalovirus IE86 protein is necessary for efficient virus replication. J. Virol., 2006, 80 (8), 3872-3883.
74. Castillo, J.P.; Kowalik, T.F. Human cytomegalovirus immediate early proteins and cell growth control. Gene, 2002, 290 (1-2), 19-34.
75. Lokensgard, J.R.; Cheeran, M.C.; Gekker, G.; Hu, S.; Chao, C.C.; Peterson, P.K. Human cytomegalovirus replication and modulation of apoptosis in astrocytes. J. Hum. Virol., 1999, 2 (2), 91-101.
76. Hamirally, S.; Kamil, J.P.; Ndassa-Colday, Y.M.; Lin, A.J.; Jahng, W.J.; Baek, M.C.; Noton, S.; Silva, L.A.; Simpson-Holley, M.; Knipe, D.M.; Golan, D.E.; Marto, J.A.; Coen, D.M. Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. PLoS Pathog., 2009, 5 (1), e1000275.
77. Prichard, M.N. Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev. Med. Virol., 2009, 19 (4), 215-229.
78. Luleci, G.; Sakizli, M.; Gunalp, A. Selective chromosomal damage caused by human cytomegalovirus. Acta. Virol., 1980, 24 (5), 341-345.
79. AbuBakar, S.; Au, W.W.; Legator, M.S.; Albrecht, T. Induction of chromosome aberrations and mitotic arrest by cytomegalovirus in human cells. Environ. Mol. Mutagen., 1988, 12 (4), 409-420.
80. Fortunato, E.A.; Dell'Aquila, M.L.; Spector, D.H. Specific chromosome 1 breaks induced by human cytomegalovirus. Proc. Natl. Acad. Sci. USA, 2000, 97 (2), 853-858.
81. Fagerheim, T.; Nilssen, O.; Raeymaekers, P.; Brox, V.; Moum, T.; Elverland, H.H.; Teig, E.; Omland, H.H.; Fostad, G.K.; Tranebjaerg, L. Identification of a new locus for autosomal dominant non-syndromic hearing impairment (DFNA7) in a large Norwegian family. Hum. Mol. Genet., 1996, 5 (8), 1187-1191.
82. Eudy, J.D.; Weston, M.D.; Yao, S.; Hoover, D.M.; Rehm, H.L.; Ma-Edmonds, M.; Yan, D.; Ahmad, I.; Cheng, J.J.; Ayuso, C.; Cremers, C.; Davenport, S.; Moller, C.; Talmadge, C.B.; Beisel, K.W.; Tamayo, M.; Morton, C.C.; Swaroop, A.; Kimberling, W.J.; Sumegi, J. Mutation of a gene encoding a protein with extracellular matrix motifs in Usher syndrome type IIa. Science, 1998, 280 (5370), 1753-1757.
83. Sumegi, J.; Wang, J.Y.; Zhen, D.K.; Eudy, J.D.; Talmadge, C.B.; Li, B.F.; Berglund, P.; Weston, M.D.; Yao, S.F.; Ma-Edmonds, M.; Overbeck, L.; Kelley, P.M; Zabarovsky, E.; Uzvolgyi, E.; Stanbridge, E.J.; Klein, G.; Kimberling, W.J. The construction of a yeast artificial chromosome (YAC) contig in the vicinity of the Usher syndrome type IIa (USH2A) gene in 1q41. Genomics, 1996, 35 (1), 79-86.
84. Nystad, M.; Fagerheim, T.; Brox, V.; Fortunato, E.A.; Nilssen, O. Human cytomegalovirus (HCMV) and hearing impairment: Infection of fibroblast cells with HCMV induces chromosome breaks at 1q23.3, between loci DFNA7 and DFNA49-Both involved in dominantly inherited, sensorineural, hearing impairment. Mutat. Res., 2008, 637 (1-2), 56-65.
85. Siew, V.K.; Duh, C.Y.; Wang, S.K. Human cytomegalovirus UL76 induces chromosome aberrations. J. Biomed. Sci., 2009, 16, 107.
86. Munger, J.; Bajad, S.U.; Coller, H.A.; Shenk, T.; Rabinowitz, J.D. Dynamics of the cellular metabolome during human cytomegalovirus infection. PLoS Pathog., 2006, 2 (12), e132.
87. Munger, J.; Bennett, B.D.; Parikh, A.; Feng, X.J.; McArdle, J.; Rabitz, H.A.; Shenk, T.; Rabinowitz, J.D. Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat. Biotechnol., 2008, 26 (10), 1179-1186.
88. McArdle, J.; Schafer, X.L.; Munger, J. Inhibition of calmodulindependent kinase kinase blocks human cytomegalovirus-induced glycolytic activation and severely attenuates production of viral progeny. J. Virol., 2011, 85 (2), 705-714.
89. Le, Y.; Gong, W.; Shen, W.; Li, B.; Dunlop, N.M.; Wang, J.M. A burgeoning family of biological mediators: chemokines and chemokine receptors. Arch. Immunol. Ther. Exp. (Warsz)., 2000, 48 (3), 143-150.
90. Kotenko, S.V.; Saccani, S.; Izotova, L.S.; Mirochnitchenko, O.V.; Pestka, S.: Human cytomegalovirus harbors its own unique IL-10 homolog (cmvIL-10). Proc. Natl. Acad. Sci. USA, 2000, 97 (4), 1695-1700.
91. Spencer, J.V.; Lockridge, K.M.; Barry, P.A.; Lin, G.; Tsang, M.; Penfold, M.E.; Schall, T.J. Potent immunosuppressive activities of cytomegalovirus-encoded interleukin-10. J. Virol., 2002, 76 (3), 1285-1292.
92. Raftery, M.J.; Wieland, D.; Gronewald, S.; Kraus, A.A.; Giese, T.; Schönrich, G. Shaping phenotype, function, and survival of dendritic cells by cytomegalovirus-encoded IL-10. J. Immunol., 2004, 173 (5), 3383-3391.
93. Chang, W.L.; Baumgarth, N.; Yu, D.; Barry, P.A. Human cytomegalovirus- encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J. Virol., 2004, 78 (16), 8720-8731.
94. de Lemos Rieper, C.; Galle, P.; Pedersen, B.K.; Hansen, M.B. Characterization of specific antibodies against cytomegalovirusencoded IL-10 produced by 28% of the CMV-seropositive blood donors. J. Gen. Virol., 2011, 92 (Pt7), 1508-1518.
95. Roth, I.; Fisher, S.J. IL-10 is an autocrine inhibitor of human placental cytotrophoblast MMP-9 production and invasion. Dev. Biol., 1999, 205 (1), 194-204.
96. Yamamoto-Tabata, T.; McDonagh, S.; Chang, H.T.; Fisher, S.; Pereira, L. Human cytomegalovirus interleukin-10 downregulates metalloproteinase activity and impairs endothelial cell migration and placental cytotrophoblast invasiveness in vitro. J. Virol., 2004, 78 (6), 2831-2840.
97. Penfold, M.E.; Dairaghi, D.J.; Duke, G.M.; Saederup, N.; Mocarski, E.S.; Kemble, G.W.; Schall, T.J. Cytomegalovirus encodes a potent alpha chemokine. Proc. Natl. Acad. Sci. USA, 1999, 96 (17), 9839-9844.
98. Hahn, G.; Revello, M.G.; Patrone, M.; Percivalle, E.; Campanini, G.; Sarasini, A.; Wagner, M.; Gallina, A.; Milanesi, G.; Koszinowski, U.; Baldanti, F.; Gerna, G. Human cytomegalovirus UL131-128 genes are indispensable for virus growth in endothelial cells and virus transfer to leukocytes. J. Virol., 2004, 78 (18), 10023-10033.
99. Benedict, C.A.; Butrovich, K.D.; Lurain, N.S.; Corbeil, J.; Rooney, I.; Schneider, P.; Tschopp, J.; Ware, C.F. Cutting edge: a novel viral TNF receptor superfamily member in virulent strains of human cytomegalovirus. J. Immunol., 1999, 162 (12), 6967-6970.
100. Lurain, N.S.; Kapell, K.S.; Huang, D.D.; Short, J.A.; Paintsil, J.; Winkfield, E.; Benedict, C.A.; Ware, C.F.; Bremer, J.W. Human cytomegalovirus UL144 open reading frame: sequence hypervariability in low-passage clinical isolates. J. Virol., 1999, 73 (12), 10040-10050.
101. Poole, E.; King, C.A.; Sinclair, J.H.; Alcami, A. The UL144 gene product of human cytomegalovirus activates NFkappaB via a TRAF6-dependent mechanism. EMBO J., 2006, 25 (18), 4390-4399.
102. Vischer, H.F.; Vink, C.; Smit, M.J. A viral conspiracy: hijacking the chemokine system through virally encoded pirated chemokine receptors. Curr. Top. Microbiol. Immunol., 2006, 303, 121-154.
103. Beisser, P.S.; Lavreysen, H.; Bruggeman, C.A.; Vink, C. Chemokines and chemokine receptors encoded by cytomegaloviruses. Curr. Top. Microbiol. Immunol., 2008, 325, 221-242.
104. Vomaske, J.; Nelson, J.A.; Streblow, D.N. Human cytomegalovirus US28: a functionally selective chemokine binding receptor. Infect. Disord. Drug Targets, 2009, 9 (5), 548-556.
105. Chapman, T.L.; Heikeman, A.P.; Bjorkman, P.J. The inhibitory receptor LIR-1 uses a common binding interaction to recognize class I MHC molecules and the viral homolog UL18. Immunity, 1999, 11 (5), 603-613.
106. Yang, Z.; Bjorkman, P.J. Structure of UL18, a peptide-binding viral MHC mimic, bound to a host inhibitory receptor. Proc. Natl. Acad. Sci. USA, 2008, 105 (29), 10095-10100.
107. Occhino, M.; Ghiotto, F.; Soro, S.; Mortarino, M.; Bosi, S.; Maffei, M.; Bruno, S.; Nardini, M.; Figini, M.; Tramontano, A.; Ciccone, E. Dissecting the structural determinants of the interaction between the human cytomegalovirus UL18 protein and the CD85j immune receptor. J. Immunol., 2008, 180 (2), 957-968.
108. Wills, M.R.; Ashiru, O.; Reeves, M.B.; Okecha, G.; Trowsdale, J.; Tomasec, P.; Wilkinson, G.W.; Sinclair, J.; Sissons, J.G. Human cytomegalovirus encodes an MHC class I-like molecule (UL142) that functions to inhibit NK cell lysis. J. Immunol., 2005, 175 (11), 7457-7465.
109. Chalupny, N.J.; Rein-Weston, A.; Dosch, S.; Cosman, D. Downregulation of the NKG2D ligand MICA by the human cytomegalovirus glycoprotein UL142. Biochem. Biophys. Res. Commun., 2006, 346 (1), 175-181.
110. Powers, C.; DeFilippis, V.; Malouli, D.; Früh, K. Cytomegalovirus immune evasion. Curr. Top. Microbiol. Immunol., 2008, 325, 333-359.
111. Marshall, E.E.; Geballe, A.P. Multifaceted evasion of the interferon response by cytomegalovirus. J. Interferon Cytokine Res., 2009, 29 (9), 609-619.
112. Paulus, C.; Krauss, S.; Nevels, M. A human cytomegalovirus antagonist of type I IFN-dependent signal transducer and activator of transcription signaling. Proc. Natl. Acad. Sci. USA, 2006, 103 (10), 3840-3845.
113. Huh, Y.H.; Kim, Y.E.; Kim, E.T.; Park, J.J.; Song, M.J.; Zhu, H.; Hayward, G.S.; Ahn, J.H. Binding STAT2 by the acidic domain of human cytomegalovirus IE1 promotes viral growth and is negatively regulated by SUMO. J. Virol., 2008, 82 (21), 10444-10454.
114. Taylor, R.T.; Bresnahan, W.A. Human cytomegalovirus immediate- early 2 gene expression blocks virus-induced beta interferon production. J. Virol., 2005, 79 (6), 3873-3877.
115. DeFilippis, V.R. Induction and evasion of the type I interferon response by cytomegaloviruses. Adv. Exp. Med. Biol., 2007, 598, 309-324.
116. Unterholzner, L.; Bowie, A.G. The interplay between viruses and innate immune signaling: recent insights and therapeutic opportunities. Biochem. Pharmacol., 2008, 75 (3), 589-602.
117. Child, S.J.; Hakki, M.; De Niro, K.L.; Geballe, A.P. Evasion of cellular antiviral responses by human cytomegalovirus TRS1 and IRS1. J. Virol., 2004, 78 (1), 197-205.
118. Marshall, E.E.; Bierle, C.J.; Brune, W.; Geballe, A.P. Essential role for either TRS1 or IRS1 in human cytomegalovirus replication. J. Virol., 2009, 83 (9), 4112-4120.
119. Jones, T.R.; Hanson, L.K.; Sun, L.; Slater, J.S.; Stenberg, R.M.; Campbell, A.E. Multiple independent loci within the human cytomegalovirus unique short region down-regulate expression of major histocompatibility complex class I heavy chains. J. Virol., 1995, 69 (8), 4830-4841.
120. Ahn, K.; Angulo, A.; Ghazal, P.; Peterson, P.A.; Yang, Y.; Fruh, K. Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. Proc. Natl. Acad. Sci. USA, 1996, 93 (20), 10990-10995.
121. Jones, T.R.; Wiertz, E.J.; Sun, L.; Fish, K.N.; Nelson, J.A.; Ploegh, H.L. Human cytomegalovirus US3 impairs transport and maturation of major histocompatibility complex class I heavy chains. Proc. Natl. Acad. Sci. USA, 1996, 93 (21), 11327-11333.
122. Wiertz, E.J.; Tortorella, D.; Bogyo, M.; Yu, J.; Mothes, W.; Jones, T.R.; Rapoport, T.A.; Ploegh, H.L. Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. Nature, 1996, 384 (6608), 432-438.
123. Wiertz, E.J.; Jones, T.R.; Sun, L.; Bogyo, M.; Geuze, H.J.; Ploegh, H.L. The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. Cell, 1996, 84 (5), 769-779.
124. Ahn, K.; Gruhler, A.; Galocha, B.; Jones, T.R.; Wiertz, E.J.; Ploegh, H.L.; Peterson, P.A.; Yang, Y.; Fruh, K. The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. Immunity, 1997, 6 (5), 613-621.
125. Hengel, H.; Koopmann, J.O.; Flohr, T.; Muranyi, W.; Goulmy, E.; Hammerling, G.J.; Koszinowski, U.H.; Momburg, F. A viral ERresident glycoprotein inactivates the MHC-encoded peptide transporter. Immunity, 1997, 6 (5), 623-632.
126. Jun, Y.; Kim, E.; Jin, M.; Sung, H.C.; Han, H.; Geraghty, D.E.; Ahn, K. Human cytomegalovirus gene products US3 and US6 down-regulate trophoblast class I MHC molecules. J. Immunol., 2000, 164 (2), 805-811.
127. Jones, T. R.; Muzithras, V.P. 1992. A cluster of dispensable genes within the human cytomegalovirus genome short component: IRS1, US1 through US5, and the US6 family. J. Virol., 1992, 66 (4), 2541-2546.
128. Dölken, L.; Pfeffer, S.; Koszinowski, U.H. Cytomegalovirus microRNAs. Virus Genes, 2009, 38 (3), 355-364.
129. Fannin Rider, P.J.; Dunn, W.; Yang, E.; Liu, F. Human cytomegalovirus microRNAs. Curr. Top. Microbiol. Immunol., 2008, 325, 21-39.
130. Grey, F.; Nelson, J. Identification and function of human cytomegalovirus microRNAs. J. Clin. Virol., 2008, 41 (3), 186-191.
131. Stern-Ginossar, N.; Elefant, N.; Zimmermann, A.; Wolf, D.G.; Saleh, N.; Biton, M.; Horwitz, E.; Prokocimer, Z.; Prichard, M.; Hahn, G.; Goldman-Wohl, D.; Greenfield, C.; Yagel, S.; Hengel, H.; Altuvia, Y.; Margalit, H.; Mandelboim, O. Host immune system gene targeting by a viral miRNA. Science, 2007, 317 (5836), 376-381.
132. Nachmani, D.; Lankry, D.; Wolf, D.G.; Mandelboim, O. The human cytomegalovirus microRNA miR-UL112 acts synergistically with a cellular microRNA to escape immune elimination. Nat. Immunol., 2010, 11 (9), 806-813.
133. Wilkinson, G.W.; Tomasec, P.; Stanton, R.J.; Armstrong, M.; Prod'homme, V.; Aicheler, R.; McSharry, B.P.; Rickards, C.R.; Cochrane, D.; Llewellyn-Lacey, S.; Wang, E.C.; Griffin, C.A.; Davison, A.J. Modulation of natural killer cells by human cytomegalovirus. J. Clin. Virol., 2008, 41 (3), 206-212.
134. Stern-Ginossar, N.; Saleh, N.; Goldberg, M.D.; Prichard, M.; Wolf, D.G.; Mandelboim, O. Analysis of human cytomegalovirusencoded microRNA activity during infection. J. Virol., 2009, 83 (20), 10684-10693.
135. Grey, F.; Meyers, H.; White, E.A.; Spector, D.H.; Nelson, J. A human cytomegalovirus-encoded microRNA regulates expression of multiple viral genes involved in replication. PLoS Pathog., 2007, 3 (11), e163.
136. Meyer, C.; Grey, F.; Kreklywich, C.N.; Andoh, T.F.; Tirabassi, R.S.; Orloff, S.L.; Streblow, D.N. Cytomegalovirus microRNA expression is tissue specific and is associated with persistence. J. Virol., 2011, 85 (1), 378-389.
137. Dölken, L.; Krmpotic, A.; Kothe, S.; Tuddenham, L.; Tanguy, M.; Marcinowski, L.; Ruzsics, Z.; Elefant, N.; Altuvia, Y.; Margalit, H.; Koszinowski, U.H.; Jonjic, S.; Pfeffer, S. Cytomegalovirus mi croRNAs facilitate persistent virus infection in salivary glands. PLoS Pathog., 2010, 6 (10), e1001150.
138. Grey, F.; Tirabassi, R.; Meyers, H.; Wu, G.; McWeeney, S.; Hook, L.; Nelson, J.A. A viral microRNA down-regulates multiple cell cycle genes through mRNA 5'UTRs. PLoS Pathog., 2010, 6 (6), e1000967.
139. Wang, F.Z.; Weber, F.; Croce, C.; Liu, C.G.; Liao, X.; Pellett, P.E. Human cytomegalovirus infection alters the expression of cellular microRNA species that affect its replication. J. Virol., 2008, 82 (18), 9065-9074.
140. Moens, U. Silencing viral microRNA as a novel antiviral therapy? J. Biomed. Biotechnol., 2009, 2009, 419539.
141. Hansson, G.K.; Robertson, A.K.; Söderberg-Nauclér, C. Inflammation and atherosclerosis. Annu. Rev. Pathol., 2006, 1, 297-329.
142. Chen, R.; Xiong, S.; Yang, Y.; Fu, W.; Wang, Y.; Ge, J. The relationship between human cytomegalovirus infection and atherosclerosis development. Mol. Cell Biochem., 2003, 249 (1-2), 91-96.
143. Streblow, D.N.; Söderberg-Nauclér, C.; Vieira, J.; Smith, P.; Wakabayashi, E.; Ruchti, F.; Mattison, K.; Altschuler, Y.; Nelson, J.A. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell, 1999, 99 (5), 511-520.
144. Tanaka, K.; Zou, J.P.; Takeda, K.; Ferrans, V.J.; Sandford, G.R.; Johnson, T.M.; Finkel, T.; Epstein, S.E. Effects of human cytomegalovirus immediate-early proteins on p53-mediated apoptosis in coronary artery smooth muscle cells. Circulation, 1999, 99 (13), 1656-1659.
145. Zhou, Y.F.; Yu, Z.X.; Wanishsawad, C.; Shou, M.; Epstein, S.E. The immediate early gene products of human cytomegalovirus increase vascular smooth muscle cell migration, proliferation, and expression of PDGF beta-receptor. Biochem. Biophys. Res. Commun., 1999, 256 (3), 608-613.
146. Botto, S.; Streblow, D.N.; DeFilippis, V.; White, L.; Kreklywich, C.N.; Smith, P.P. Caposio, P. IL-6 in human cytomegalovirus secretome promotes angiogenesis and survival of endothelial cells through the stimulation of survivin. Blood, 2011, 117 (1), 352-361.
147. Persoons, M.C.; Stals, F.S.; van dam Mieras, M.C.; Bruggeman, C.A. Multiple organ involvement during experimental cytomegalovirus infection is associated with disseminated vascular pathology. J. Pathol., 1998, 184 (1), 103-109.
148. Corona-Rivera, J.R.; Corona-Rivera, E.; Romero-Velarde, E.; Hernández-Rocha, J.; Bobadilla-Morales, L.; Corona-Rivera, A. Report and review of the fetal brain disruption sequence. Eur. J. Pediatr., 2001, 160 (11), 664-667.
149. Mendelson, M.; Monard, S.; Sissons, P.; Sinclair, J. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J. Gen. Virol., 1996, 77 (pt. 12), 3099-3102.
150. Taylor-Wiedeman, J.; Sissons, J.G.; Borysiewicz, L.K.; Sinclair, J.H. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J. Gen. Virol., 1991, 72 (pt. 9), 2059-2064.
151. Hahn, G.; Jores, R.; Mocarski, E.S. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc. Natl. Acad. Sci. USA, 1998, 95 (7), 3937-3942.
152. Söderberg-Nauclér, C.; Fish, K.N.; Nelson, J.A. Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines. J. Clin. Invest., 1997, 100 (12), 3154-3163.
153. Söderberg-Nauclér C.; Streblow, D.N.; Fish, K.N.; Allan-Yorke, J.; Smith, P.P.; Nelson, J.A. Reactivation of latent human cytomegalovirus in CD14 (+) monocytes is differentiation dependent. J. Virol., 2001, 75 (16), 7543-7554.
154. Kondo, K.; Kaneshima, H.; Mocarski, E.S. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc. Natl. Acad. Sci. USA, 1994, 91 (25), 11879-11883.
155. Kondo K.; Xu, J.; Mocarski, E.S. Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals. Proc. Natl. Acad. Sci. USA, 1996, 93 (20), 11137-11142.
156. von Laer D.; Meyer-Koenig, U.; Serr, A.; Finke, J.; Kanz, L.; Fauser, A.A.; Neumann-Haefelin, D.; Brugger, W.; Hufert, F.T. Detection of cytomegalovirus DNA in CD34+ cells from blood and bone marrow. Blood, 1995, 86 (11), 4086-4090.
157. Goodrum, F.D.; Jordan, C.T.; High, K.; Shenk, T. Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. Proc. Natl. Acad. Sci. USA, 2002, 99 (25), 16255-16260.
158. Goodrum, F.; Reeves, M.; Sinclair, J.; High, K.; Shenk, T. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood, 2007, 110 (3), 937-945.
159. Petrucelli, A.; Rak, M.; Grainger, L.; Goodrum, F. Characterization of a novel Golgi apparatus-localized latency determinant encoded by human cytomegalovirus. J. Virol., 2009, 83 (11), 5615-5629.
160. Söderberg-Nauclér, C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J. Intern. Med., 2006, 259 (3), 219-246.
161. Zilfou, J.T.; Lowe, S.W. Tumor suppressive functions of p53. Cold Spring Harb. Perspect. Biol., 2009, 1 (5), a001883.
162. Prichard, M.N.; Sztul, E.; Daily, S.L.; Perry, A.L.; Frederick, S.L.; Gill, R.B.; Hartline, C.B.; Streblow, D.N.; Varnum, S.M.; Smith, R.D.; Kern, E.R. Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J. Virol., 2008, 82 (10), 5054-5067.
163. Helt, A.M.; Galloway, D.A. Mechanisms by which DNA tumor virus oncoproteins target the Rb family of pocket proteins. Carcinogenesis, 2003, 24 (2),159-169.
164. Kamil, J.P.; Hume, A.J.; Jurak, I.; Münger, K.; Kalejta, R.F.; Coen, D.M. Human papillomavirus 16 E7 inactivator of retinoblastoma family proteins complements human cytomegalovirus lacking UL97 protein kinase. Proc. Natl. Acad. Sci. USA, 2009, 106 (39), 16823-16828.
165. Kalejta, R.F.; Shenk, T. Proteasome-dependent, ubiquitin independent degradation of the Rb family of tumor suppressors by the human cytomegalovirus pp71 protein. Proc. Natl. Acad. Sci. USA, 2003, 100 (6), 3263-3268.
166. Kalejta, R.F.; Bechtel, J.T.; Shenk, T. Human cytomegalovirus pp71 stimulates cell cycle progression by inducing the proteasomedependent degradation of the retinoblastoma family of tumor suppressors. Mol. Cell Biol., 2003, 23 (6), 1885-1895.
167. Boldogh, I.; AbuBakar, S.; Albrecht, T. Activation of protooncogenes: an immediate early event in human cytomegalovirus infection. Science, 1990, 247 (4942), 561-564.
168. Muralidhar, S.; Doniger, J.; Mendelson, E.; Araujo, J.C.; Kashanchi, F.; Azumi, N.; Brady, J.N.; Rosenthal, L.J. Human cytomegalovirus mtrII oncoprotein binds to p53 and downregulates p53-activated transcription. J. Virol., 1996, 70 (12), 8691-8700.
169. Doniger, J.; Muralidhar, S.; Rosenthal, L.J. Human cytomegalovirus and human herpesvirus 6 genes that transform and transactivate. Clin. Microbiol. Rev., 1999, 12 (3), 367-382.
170. Picone, O.; Costa, J.M.; Chaix, M.L.; Ville, Y.; Rouzioux, C.; Leruez-Ville, M. Human cytomegalovirus UL144 gene polymorphisms in congenital infections. J. Clin. Microbiol., 2005, 43 (1), 25-29.
171. Mao, Z.Q.; He, R.; Sun, M.; Qi, Y.; Huang, Y.J.; Ruan, Q. The relationship between polymorphisms of HCMV UL144 ORF and clinical manifestations in 73 strains with congenital and/or perinatal HCMV infection. Arch. Virol., 2007, 152 (1), 115-124.
172. Heo, J.; Petheram, S.; Demmler, G.; Murph, J.R.; Adler, S.P.; Bale, J.; Sparer, T.E. Polymorphisms within human cytomegalovirus chemokine (UL146/UL147) and cytokine receptor genes (UL144) are not predictive of sequelae in congenitally infected children. Virology, 2008, 378 (1), 86-96. Erratum in: Virology, 2008, 383 (1), 168-171.
173. Arav-Boger, R.; Foster, C.B.; Zong, J.C.; Pass, R.F. Human cytomegalovirus-encoded alpha-chemokines exhibit high sequence variability in congenitally infected newborns. J. Infect. Dis., 2006, 193 (6), 788-791.
174. Pignatelli, S.; Dal Monte, P.; Rossini, G.; Lazzarotto, T.; Gatto, M.R.; Landini, M.P. Intrauterine cytomegalovirus infection and glycoprotein N (gN) genotypes. J. Clin. Virol., 2003, 28 (1), 38-43.
175. Jin, H.; Wang, X.; Li, S. Human cytomegalovirus glycoprotein B genotype correlates with different symptoms of infected infants. Intervirology, 2007, 50 (3), 219-223.
176. Arav-Boger, R.; Boger, Y.S.; Foster, C.B.; Boger, Z. The use of artificial neural networks in prediction of congenital CMV outcome from sequence data. Bioinform. Biol. Insights, 2008, 2, 281-289.
177. Koedood, M.; Fichtel, A.; Meier, P.; Mitchell, PJ. Human cytomegalovirus (HCMV) immediate-early enhancer/promoter specificity during embryogenesis defines target tissues of congenital HCMV infection. J. Virol., 1995, 69 (4), 2194-2207.
178. Mocarski, E.S.; Bonyhadi, M.; Salimi, S.; McCune, J.M.; Kaneshima, H. Human cytomegalovirus in a SCID-hu mouse: thymic epithelial cells are prominent targets of viral replication. Proc. Natl. Acad. Sci. USA, 1993, 90 (1), 104-108.
179. Barry, P.A.; Lockridge, K.M.; Salamat, S.; Tinling, S.P.; Yue, Y.; Zhou, S.S.; Gospe, S.M.; Britt, W.J.; Tarantal, A.F. Nonhuman primate models of intrauterine cytomegalovirus infection. ILAR J., 2006, 47 (1), 49-64.
180. Tsutsui, Y.; Kosug, I.; Kawasaki, H. Neuropathogenesis in cytomegalovirus infection: indication of the mechanisms using mouse models. Rev. Med. Virol., 2005, 15 (5), 327-345.
181. Tsutsui, Y.; Kosugi, I.; Kawasaki, H.; Arai, Y.; Han, G.P.; Li, L.; Kaneta, M. Roles of neural stem progenitor cells in cytomegalovirus infection of the brain in mouse models. Pathol. Int., 2008, 58 (5), 257-267.
182. Baskar, J.F.; Stanat, S.C.; Sulik, K.K.; Huang, E.S. Murine cytomegalovirus-induced congenital defects and fetal maldevelopment. J. Infect. Dis., 1983, 148 (5), 836-843.
183. Baskar, J.F.; Peacock, J.; Sulik, K.K.; Huang, E.S. Early-stage developmental abnormalities induced by murine cytomegalovirus. J. Infect. Dis., 1987, 155 (4), 661-666.
184. Schleiss, M.R. Nonprimate models of congenital cytomegalovirus (CMV) infection: gaining insight into pathogenesis and prevention of disease in newborns. ILAR J., 2006, 47 (1), 65-72.
185. Adler, H.; Messerle, M.; Koszinowski, U.H. Cloning of herpesviral genomes as bacterial artificial chromosomes. Rev. Med. Virol., 2003, 13 (12), 111-121.
186. Borst, E.M.; Crnkovic-Mertens, I.; Messerle, M. Cloning of betaherpesvirus genomes as bacterial artificial chromosomes. Methods Mol. Biol., 2004, 256, 221-239.
187. Ruzsics, Z.; Koszinowski, U.H. Mutagenesis of the cytomegalovirus genome. Curr. Top. Microbiol. Immunol., 2008, 325, 41-61.
188. Cicin-Sain, L.; Bubić, I.; Schnee, M.; Ruzsics, Z.; Mohr, C.; Jonjić S.; Koszinowski, U.H. Targeted deletion of regions rich in immune-evasive genes from the cytomegalovirus genome as a novel vaccine strategy. J. Virol., 2007, 81 (24), 13825-13834.
189. Crumpler, M.M.; Choi, K.Y.; McVoy, M.A.; Schleiss, M.R. A live guinea pig cytomegalovirus vaccine deleted of three putative immune evasion genes is highly attenuated but remains immunogenic in a vaccine/challenge model of congenital cytomegalovirus infection. Vaccine, 2009, 27 (31), 4209-4218.
190. McCarthy, F.P.; Giles, M.L.; Rowlands, S.; Purcell, K.J.; Jones, C.A. Antenatal interventions for preventing the transmission of cytomegalovirus (CMV) from the mother to fetus during pregnancy and adverse outcomes in the congenitally infected infant. Cochrane Database Syst. Rev., 2011, 3, CD008371.